Latest Breaking News On - Improves functional assessments - Page 1 : comparemela.com

Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting News provided by Share this article Share this article BOSTON, May 17, 2021 /PRNewswire/  Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is presenting a poster at the 2021 American College of Cardiology (ACC) meeting being held virtually from May 15-17, 2021. The poster entitled Elamipretide Improves Functional Assessments when Compared to the Natural History Progression of Cardiomyopathy-related Disease Symptomatology in Patients with Barth Syndrome: A TAZPOWER Analysis presents data from a Phase 3 retrospective natural history control trial comparing the cardiac and functional effects of elamipretide on Barth syndrome patients at week 72 of the open label extension por

United statesJanhavi mohiteExchange commissionAmerican college of cardiologyJohns hopkins kennedy krieger instituteStealth biotherapeutics corp nasdaqStealth biotherapeutics incImproves functional assessmentsNatural history progressionCardiomyopathy related disease symptomatologyBarth syndromeHistory controlJohns hopkins kennedy kriegerPrivate securities litigation reform actAnnual reportஒன்றுபட்டது மாநிலங்களில்